263 related articles for article (PubMed ID: 27025445)
21. Validation of a rodent model of Parkinson's Disease: evidence of a therapeutic window for oral Sinemet.
Lindner MD; Plone MA; Francis JM; Emerich DF
Brain Res Bull; 1996; 39(6):367-72. PubMed ID: 9138746
[TBL] [Abstract][Full Text] [Related]
22. Effects of amphetamine on pro-social ultrasonic communication in juvenile rats: Implications for mania models.
Engelhardt KA; Fuchs E; Schwarting RKW; Wöhr M
Eur Neuropsychopharmacol; 2017 Mar; 27(3):261-273. PubMed ID: 28119084
[TBL] [Abstract][Full Text] [Related]
23. Upregulation of striatal adenosine A2A receptor mRNA in 6-hydroxydopamine-lesioned rats intermittently treated with L-DOPA.
Tomiyama M; Kimura T; Maeda T; Tanaka H; Kannari K; Baba M
Synapse; 2004 Jun; 52(3):218-22. PubMed ID: 15065221
[TBL] [Abstract][Full Text] [Related]
24. Manipulation of vocal communication and anxiety through pharmacologic modulation of norepinephrine in the Pink1-/- rat model of Parkinson disease.
Hoffmeister JD; Kelm-Nelson CA; Ciucci MR
Behav Brain Res; 2022 Feb; 418():113642. PubMed ID: 34755639
[TBL] [Abstract][Full Text] [Related]
25. [Treatment of patients with vascular parkinsonism with the preparations nakom and madopar].
Kamenetskiĭ VK
Klin Med (Mosk); 1984 Apr; 62(4):112-6. PubMed ID: 6737958
[No Abstract] [Full Text] [Related]
26. Parkinsonism from methanol poisoning: benefit from treatment with anti-Parkinson drugs.
Davis LE; Adair JC
Mov Disord; 1999 May; 14(3):520-2. PubMed ID: 10348484
[No Abstract] [Full Text] [Related]
27. CART modulates the effects of levodopa in rat model of Parkinson's disease.
Upadhya MA; Shelkar GP; Subhedar NK; Kokare DM
Behav Brain Res; 2016 Mar; 301():262-72. PubMed ID: 26771081
[TBL] [Abstract][Full Text] [Related]
28. Somatic delivery of catecholamines in the striatum attenuate parkinsonian symptoms and widen the therapeutic window of oral sinemet in rats.
Lindner MD; Plone MA; Mullins TD; Winn SR; Chandonait SE; Stott JA; Blaney TJ; Sherman SS; Emerich DF
Exp Neurol; 1997 May; 145(1):130-40. PubMed ID: 9184116
[TBL] [Abstract][Full Text] [Related]
29. Reduction of dopamine synaptic activity: degradation of 50-kHz ultrasonic vocalization in rats.
Ciucci MR; Ahrens AM; Ma ST; Kane JR; Windham EB; Woodlee MT; Schallert T
Behav Neurosci; 2009 Apr; 123(2):328-36. PubMed ID: 19331456
[TBL] [Abstract][Full Text] [Related]
30. Drugs for Parkinson's disease.
Treat Guidel Med Lett; 2013 Nov; 11(135):101-6. PubMed ID: 24165688
[TBL] [Abstract][Full Text] [Related]
31. Levodopa infusion does not decrease the onset of abnormal involuntary movements in parkinsonian rats.
Papathanou M; van der Laan R; Jenner P; Rose S; McCreary AC
Mov Disord; 2013 Jul; 28(8):1072-9. PubMed ID: 23125107
[TBL] [Abstract][Full Text] [Related]
32. Medical treatment of later-stage motor problems of Parkinson disease.
Ahlskog JE
Mayo Clin Proc; 1999 Dec; 74(12):1239-54. PubMed ID: 10593354
[TBL] [Abstract][Full Text] [Related]
33. Morphological dendritic spine changes of medium spiny neurons in the nucleus accumbens in 6-hydroxydopamine-lesioned rats treated with levodopa.
Funamizu Y; Nishijima H; Ueno T; Ueno S; Mizukami H; Yagihashi S; Tomiyama M
Neurosci Res; 2017 Aug; 121():49-53. PubMed ID: 28392304
[TBL] [Abstract][Full Text] [Related]
34. Neuroprotective effect of L-DOPA co-administered with the adenosine A2A receptor agonist CGS 21680 in an animal model of Parkinson's disease.
Agnati LF; Leo G; Vergoni AV; Martínez E; Hockemeyer J; Lluis C; Franco R; Fuxe K; Ferré S
Brain Res Bull; 2004 Aug; 64(2):155-64. PubMed ID: 15342103
[TBL] [Abstract][Full Text] [Related]
35. Parkinson's disease.
Barboi AC; Goetz CG
Clin Neuropharmacol; 1999; 22(4):184-91. PubMed ID: 10442246
[No Abstract] [Full Text] [Related]
36. The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments.
Schwarting RK; Huston JP
Prog Neurobiol; 1996 Oct; 50(2-3):275-331. PubMed ID: 8971983
[TBL] [Abstract][Full Text] [Related]
37. Disturbance of sensorimotor filtering in the 6-OHDA rodent model of Parkinson's disease.
Issy AC; Padovan-Neto FE; Lazzarini M; Bortolanza M; Del-Bel E
Life Sci; 2015 Mar; 125():71-8. PubMed ID: 25681528
[No Abstract] [Full Text] [Related]
38. Noradrenergic receptor modulation influences the acoustic parameters of pro-social rat ultrasonic vocalizations.
Grant LM; Barth KJ; Muslu C; Kelm-Nelson CA; Bakshi VP; Ciucci MR
Behav Neurosci; 2018 Aug; 132(4):269-283. PubMed ID: 29985007
[TBL] [Abstract][Full Text] [Related]
39. Dissociation of metabolic and hemodynamic levodopa responses in the 6-hydroxydopamine rat model.
Lerner RP; Bimpisidis Z; Agorastos S; Scherrer S; Dewey SL; Cenci MA; Eidelberg D
Neurobiol Dis; 2016 Dec; 96():31-37. PubMed ID: 27544483
[TBL] [Abstract][Full Text] [Related]
40. Neurochemical responses to 6-hydroxydopamine and L-dopa therapy: implications for Parkinson's disease.
Zigmond MJ; Hastings TG; Abercrombie ED
Ann N Y Acad Sci; 1992 May; 648():71-86. PubMed ID: 1637074
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
